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Serum anti-p53 autoantibodies from patients with
idiopathic pulmonary fibrosis associated with lung
cancer
K. OSHIKAWA AND Y. SUGIYAMA
Department of Pulmonary Medicine, Jichi Medical School, Kawachi-gun Tochigi, Japan
Mutations of the tumour suppressor gene p53 lead to accumulation of the mutated p53 protein and subsequent
production of antoantibodies against p53 proteins, which are also detected in lung cancer. Lung cancer is frequently
associated with idiopathic pulmonary fibrosis (IPF). Therefore, we hypothesized that there might be a relationship
between the p53mutation and high prevalence of lung cancer in IPF. To test this hypothesis, we measured serum p53
antibody levels by an ELISA in various lung diseases including lung cancer (n¼98), IPF (n¼46; with lung cancer,
n¼14 and without lung cancer, n¼32), pulmonary emphysema (PE, n¼23) and healthy controls (HC, n¼93). The
median values of the serum anti-p53 antibody in each group were 8?78, 9?18, 8?08 and 4?95 for patients with lung
cancer, IPF with lung cancer, IPF without lung cancer and PE, respectively, and 2?2 for the healthy control group.
The groups of IPF (with and without lung cancer) showed a similar level of median values to the lung cancer group
and a tendency for a higher level than the PE group. When the cut-off value was set at 7?7 according to the 95%
specificity level for normal control, the incidence of positive anti-p53 antibody was significantly higher in lung cancer
(61?2%), IPF with lung cancer (57?1%) and IPF without lung cancer (53?1%) than PE (21?7%). These results
suggest that p53 mutations occur frequently and substantially in IPF, resulting in a high prevalence of lung cancer.
Key words: p53 protein; mutation; oncogene; lung cancer; idiopathic interstitial pneumonia.
RESPIR. MED. (2000) 94, 1085–1091 # 2000 HARCOURT PUBLISHERS LTD
RESPIRATORY MEDICINE (2000) 94, 1085–1091
doi:10.1053/rmed.2000.0917, available online at http://www.idealibrary.com onIntroduction
The tumour suppressor gene p53 is the most common target
for molecular alteration in human cancers (1,2). Functional
p53 is believed to sense DNA damage and activate either
DNA repair or apoptosis of the aberrant cell. Inactivation
of p53 plays a central role in the development of tumours
because p53 normally functions to inhibit the growth of
aberrant cells. Loss of normal p53 activity in a tumour cell
can occur through mutation of the p53 gene (1,2).
Mutations of the p53 gene can be assayed by such
approaches as molecular analysis by PCR amplification
followed by DNA sequencing of the p53 gene (2,3),
immunohistochemical analysis of the p53 gene product
(4,5) and measurement of antibodies to the p53 protein in
sera (6,7). In lung cancers, p53 mutations are found in 90%
of small cell lung cancers and 50% of non-small cell lung
cancers (8–10). Eighty percent of p53mutations are missense
mutations, which often lead to conformational change and
metabolic stabilization of the mutant p53 protein in theReceived 16 March 2000 and accepted in revised form 19 June
2000. Published online 18 September 2000.
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0954-6111/00/111085+07 $35?00/0nuclei (2,11,12). The accumulation of mutant p53 in tumour
cells can result in the production of anti-p53 antibody in the
serum by a self-immunization process (13,14). Serum
antibodies recognizing p53 protein have been detected in
patients with a wide variety of tumour types (6,7,13–16).
Some reports on the clinical significance of serum anti-p53
antibody measurement suggest that anti-p53 antibody may
serve as a marker for the early diagnosis of cancer, for
monitoring the response to therapy or for predicting
survival in patients with cancer (17–19).
Idiopathic pulmonary fibrosis (IPF) is an inflammatory
lung disease characterized by the accumulation of inflam-
matory cells and deposition of collagen resulting in lung
remodelling. Although the aetiology of IPF is still unknown,
it is thought that IPF begins with an initial inflammatory
lesion localized in the alveolus, then progresses to chronic
inflammation with persistent alveolitis, in which there is
progressive derangement of the alveolar structure, including
loss of type I epithelial cells, proliferation of type II cells,
migration of bronchiolar epithelial cells to the alveoli, loss
of capillaries and thickening of the walls of small airways
and arteries (20). Such an injury of the alveolar parenchymal
tissue eventually results in fibrosis of the alveolar walls as a
regenerating process. Under such a chronic inflammation
with high evolution of cell dynamics, chronic DNA damage
and subsequent p53 mutation may occur (21,22). Lung
cancer is frequently complicated by pulmonary fibrosis (20).# 2000 HARCOURT PUBLISHERS LTD
TABLE 1. Patient characteristics
Lung cancer IPF PE HC Total
Cancer (þ) Cancer (7)
No. of subjects 98 14 32 23 93 260
Male/female 69/29 8/6 21/11 18/5 49/44 165/95
Median years of age (range) 67 (37–87)* 70 (46–79)* 64 (42–84)* 70 (43–76)* 34 (20–70) 60?5 (20–87)
Smoking index
Median 900** 850 630 1000**
5600/600% 23/75 3/11 14/18 4/19
Histology
Adenocarcinoma 25 2
Epidermoid carcinoma 25 5
Small cell carcinoma 32 4
Large cell carcinoma 16 3
Stage
I 13 3
II 12 2
IIIA 14 1
IIIB 26 2
IV 33 6
Among 46 patients with IPF, 14 patients were associated with cancer and 32 had no cancer. IPF: idiopathic pulmonary
fibrosis; PE: pulmonary emphysema; HC: healthy control. *P50?0001, healthy control group vs. other groups; **P50?05,
lung cancer or PE group vs. non-lung cancer IPF patients.
1086 K. OSHIKAWA AND Y. SUGIYAMATherefore, we hypothesized that the frequent occurrence of
p53 mutation in IPF might be one of the causes of the high
frequency of lung cancer in IPF.
Several studies have indicated a positive correlation among
mutation of the p53 gene, accumulation of p53 protein and
the prevalence of serum anti-p53 antibody (6,14,15,23,24).
Measurement of the serum anti-p53 antibody level allows the
underlying p53 alteration to be estimated in a larger number
of samples. Therefore, in the present study, in order to further
analyse the relationship between the p53 gene mutation and
tumourigenesis in IPF, we assessed the serum anti-p53
antibody levels in a larger series of patients with IPF,
especially those with lung cancer and without lung cancer, as
well as the other lung disease cases, including lung cancer and
pulmonary emphysema. The clinical significance of anti-p53
antibody in IPF was also evaluated.
Materials and methods
SUBJECTS
The subjects of this study consisted of 167 patients admitted
to the Department of Pulmonary Medicine, Jichi Medical
School, Japan from 1992 to 1998 (Table 1). There were 98
patients with lung cancer, 46 with idiopathic pulmonary
fibrosis (IPF) and 23 with pulmonary emphysema (PE). The
patients with lung cancer, including 69 men and 29 women
(median age 67 years; range 37–87 years), were newly
diagnosed with histologically confirmed lung cancer during
this period. Among 46 patients with IPF diagnosed bypathological, CT (computed tomography) and clinical
findings, 14 cases were associated with lung cancer (eight
men and six women; median age 70 years; range 46–79
years); the remaining 32 cases in this IPF group were not
associated with lung cancer (21 men and 11 women; median
age, 64 years; range, 42–84 years). Based on the results of a
pulmonary function test (FEV10%555% and decline in
diffusion capacity) and the roentogenological findings of
chest radiographs and CT scan (low attenuation area and
bullous change), a clinical diagnosis of pulmonary emphy-
sema (PE) was made in 23 patients (18 men and five women;
median age, 70 years; range, 43–76 years;). As the healthy
controls (HC), serum samples were obtained from 93 normal
volunteers, including 49 men and 44 women (median age, 34
years; range, 20–70 years). There were statistically significant
differences in age between the healthy control subjects and
the other groups (P50?0001). Median values of smoking
index in the group of lung cancer, IPF with lung cancer, IPF
without lung cancer and PE were 900, 850, 630 and 1000,
respectively. Significant differences were found in the
smoking index between the lung cancer or PE group and
the non-lung cancer IPF group (P50?05).
Histological classification of the tumours was based on
the World Health Organization criteria (25). In 98 patients
with lung cancer, there were 25 adenocarcinomas, 25
epidermoid carcinomas, 32 small cell carcinomas and 16
large cell carcinomas, whereas in 14 IPF patients with lung
cancer, there were two adenocarcinomas, five epidermoid
carcinomas, four small cell carcinomas and three large cell
carcinomas. Staging for lung cancer was determined on the
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cases of lung cancer, stage I was found in 13 patients, II in
12, IIIA in 14, IIIB in 26 and IV in 33, while in 14 IPF cases
with lung cancer, stage I was found in three, II in two, IIIA
in one, IIIB in two and IV in six patients.
IPF was judged to be ‘active’ when (i) the clinical and
radiographic findings deteriorated progressively, (ii) scinti-
graphy with 67 gallium-citrate demonstrated positive uptake
in the bilateral lung fields, and (iii) when a contribution by
infection was unlikely. The disease was judged as ‘inactive’
when it did not meet these criteria. The study protocol was
approved by our institutional review board for human
studies, and written informed consent was obtained from all
the subjects.
MEASUREMENT OF SERUM ANTI-P53
ANTIBODY INDEX LEVEL
Peripheral venous blood samples were taken immediately
after hospital admission and the serum was stored at 7808C
until assay. Anti-p53 antibody index levels were determined
using a p53-autoantibody ELISA kit (Dianova, Hamburg,
Germany). Briefly, serum samples were diluted 1:100 in the
sample dilution buffer prepared with the kit. The samples were
added to 96-wells precoated with human recombinant p53
protein and incubated at 378C for 1 h. After washing, anti-p53
antibodies attached to the p53 protein of each well were
bound by peroxidase-conjugated goat anti-human IgG anti-
body. After addition of a chromogenic substrate, tetramethyl-
benzidine, the absorbance value was determined by a
microplate reader at a wavelength of 450 nm (Bio-Rad,
California, U.S.A.). The anti-p53 antibody index was
calculated using the formula: [A450 (serum sample) 7A450
(anti-p53-negative serum)]/[A450 (anti-p53-positive seru-
m)7A450 (anti-p53-negative serum)]6100. According toTABLE 2. Median value of anti-p53 antibody index level in the s
Lung cancer
Canc
Median value in each group 8?78 9
Male/female 9?1/8?0 10?43
Smoking index 5600/600% 8?25/9?35 7?6
Histology
Adenocarcinoma 9?35 10
Epidermoid carcinoma 9?20 11
Small cell carcinoma 8?65 7
Large cell carcinoma 8?33 9
Stage
I 5?50 6
II 10?25 12
IIIA 7?23 12
IIIB 10?20 10
IV 8?9 8
*Data are presented as the median values.the directions given in the procedure manual for this kit, the
presence of anti-p53 antibody in the anti-p-53-positive serum
was confirmed by Western blotting assay. All the samples
were measured in duplicate. Mean values of anti-p53 antibody
indices for each sample were used for analyses in this study.
STATISTICAL ANALYSES
Data are expressed as the median values. Differences between
the two groups were compared by the Mann–Whitney U-test.
Multi-group comparisons were made by a one-way analysis of
variance (ANOVA). The w2 and Fisher’s exact probability
tests were used for the comparison of categorical variables. A
P-value 50?05 was considered significant.
The sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) were calculated
for the anti-p53 antibody index level to analyse the optimal
criteria for discriminating between lung cancer cases and
healthy controls. Furthermore, receiver operating charac-
teristic (ROC) analysis was performed using the calculated
values for sensitivity and specificity. To estimate the
importance of factors associated with the elevated serum
anti-p53 antibody index level, multiple regression analysis
was performed.
Results
SERUM ANTI-P53 ANTIBODY INDEX
LEVELS
A total of 260 samples from 167 patients (lung cancer,
n¼98; IPF with lung cancer, n¼14; non-lung cancer IPF,
n¼32; PE, n¼23) and 93 normal volunteers were measured.
A summary of the data is shown in Table 2 and Fig. 1. Theerum according to each criteria*
IPF PE HC
er (þ) Cancer (7)
?18 8?08 4?95 2?20
/7?58 8?25/7?15 5?48/2?6 1?5/2?6
/11?4 8?23/7?7 5?4/2?8
?95
?40
?93
?45
?90
?45
?50
?60
?25
FIG. 1. Distribution of serum anti-p53 antibody index
levels for patients with lung cancer, IPF associated with or
not associated with lung cancer, pulmonary emphysema
and normal volunteers (healthy control). Values are
presented as upper and lower quartiles and range (box),
median value (horizontal line), and the middle 90%
distribution (whisker line). *P50?0001, lung cancer vs.
healthy control group; **P50?05, lung cancer vs. PE
group or non-lung cancer IPF group. IPF with or without
lung cancer means the groups of patients having or not
having lung cancer, respectively. PE, pulmonary
emphysema; HC, healthy control. The number in
parentheses indicates the number of patients in each
group.
FIG. 2. Histograms of the serum anti-p53 antibody values
in each group. The percentage of the patients whose anti-
p53 antibody was over 10 was more in the group of cancer
and IPF with/without cancer than in pulmonary
emphysema and healthy control groups.
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9?18, 8?08 and 4?95 for patients with lung cancer, IPF with
lung cancer, IPF without lung cancer and PE, respectively,
and 2?2 for the healthy control group. There were
statistically significant differences between lung cancer
and non-lung cancer IPF group (P50?05), PE (P50?05)
or the healthy control group (P50?0001). In contrast, no
significant differences in index levels were found between
the lung cancer and IPF associated with lung cancer
groups, between the IPF with and without lung cancer
groups, and between the IPF with or without lung cancer
and PE groups. Among all the groups, there were no
differences in the anti-p53 antibody index level stratified by
gender and smoking index. Furthermore, in the group of
lung cancer and IPF with lung cancer, there were no
differences in anti-p53 antibody index levels stratified by
histology and disease stage of lung cancer (Table 2).
A histogram of the serum anti-p53 antibody levels in
these five groups is shown in Fig. 2. In the PE and healthy
control groups, most patients had anti-p53 antibody levels
under 10. However, in the patients with cancer, IPF with
lung cancer and those without lung cancer, more cases had
anti-p53 antibody levels over 10, and in some of the patientswith lung cancer, anti-p53 antibody values were distributed
from 20 to 100.
THE CUT-OFF VALUE OF SERUM ANTI-P53
ANTIBODY INDEX LEVEL
Statistical measures such as sensitivity, specificity, PPV and
NPV were calculated on the basis of serum anti-p53
antibody to separate patients with lung cancer from healthy
control. Most of the parameters were over 80% when the
serum anti-p53 antibody index level was between 3?5 and
4?9. The sensitivity and specificity values were used for
ROC analysis. The ROC curve was drawn by smoothing
these points (Fig. 3). The optimal criterion, harmonizing
sensitivity and specificity, is usually defined as the closest
point to that indicating 100% sensitivity and 100%
specificity. On the ROC curve, the point corresponding to
the anti-p53 antibody value between 3?7 and 4?7 was
optimal. Therefore, when the cut-off value was set at 4?0,
the sensitivity, specificity, PPV and NPV were 84?7%,
FIG. 3. (a) When the cut-off value for the serum anti-p53
antibody index was set as 7?7 according to the 95%
specificity level for the healthy control group, the test
sensitivity (*), test specificity (*), and diagnostic
eciency were 62%, 95% and 94%, respectively. (b) Test
sensitivity and test specificity plotted on the receiver
operating characteristics curve which analyzes the lung
cancer group and healthy control group.
FIG. 4. Sensitivity of anti-p53 antibody index in each
group. The cut-off value for the serum anti-p53 antibody
index was set at 7?7 using the 95% specificity level for the
healthy control group. *P50?0000, lung cancer, IPF with
lung cancer, or IPF without lung cancer vs. healthy
control group; **P50?005, lung cancer, IPF with lung
cancer, or IPF without lung cancer vs. pulmonary
emphysema group; ***P50?05, IPF with lung cancer vs.
pulmonary emphysema group. In contrast, there were no
statistically significant differences between lung cancer
and IPF with or without lung cancer, between IPF with
and without lung cancer, and between the pulmonary
emphysema and healthy control groups.
SERUM ANTI-P53 ANTIBODY AND IPF 108981?7%, 83?0% and 83?5%, respectively. On the other hand,
when the cut-off value for the serum anti-p53 antibody
index was set at 7?7 on the basis of the 95% specificity level
for the healthy control group (27), the sensitivity, specifi-
city, PPV and NPV for lung cancer were 61?2%, 95?7% ,
93?8% and 70?1%, respectively. With this cut-off value, the
sensitivity for other groups such as IPF with lung cancer,
IPF without lung cancer, PE and healthy control group
were 57?1%, 53?1%, 21?7% and 5?0% respectively (Fig. 4).
There were statistically significant differences in lung
cancer, IPF with lung cancer or non-lung cancer IPF,
compared with the PE and healthy control group. How-
ever, no significant differences were found among the
groups with lung cancer, IPF with lung cancer and non-
lung cancer IPF. According to the histological classification
of lung cancer, the sensitivities of the anti-p53 antibody
index were 60?0% for adenocarcinoma, 64?0% for epider-
moid carcinoma, 50?0% for small cell carcinoma and
66?7% for large cell carcinoma. There were no statistically
significant differences in the tumour histological types.The factors associated with an elevated anti-p53 antibody
level in patients were further assessed using multiple
regression analysis. All the parameters including age,
gender, smoking index and presence of cancer or IPF were
analysed. As a result, it was found that the presence of
cancer was a dominant factor associated with an elevated
anti-p53 antibody index level (P¼0?0032). In contrast,
other factors, such as age, gender, smoking index and
presence of IPF, did not reach significant values.
SERUM LEVELS OF SERUM ANTI-P53
ANTIBODY IN PATIENTS WITH ACTIVE IPF
AND INACTIVE IPF
Forty-six patients with IPF were classified into two groups,
such as active IPF (n¼20) and inactive IPF (n¼26) by
clinical status. The median value of serum LDH level in the
active IPF group was 591?5 while that in the inactive IPF
group was 447?0 (P 50?05). In addition, the median value
of arterial oxygen partial pressure (PaO2) in the active IP
group was 66?3 Torr, while that in the inactive IP group
was 81?0 Torr (P50?05). However, the median values of
the serum anti-p53 antibody level in the active IP and
inactive IP groups were 8?9 and 7?28, respectively, and no
significant difference was found between these groups
(P¼0?67). As shown above, 14 of 46 patients with IPF
had lung cancer. To exclude the effect of the existence of
lung cancer on the serum anti-p53 antibody level in the IPF
group, we focused on 32 patients with non-lung cancer IPF
TABLE 3. Levels of serum anti-p53 antibody, LDH and
arterial PaO2 in the patients with active IPF and inactive
IPF*
n anti-p53
antibody
LDH
(mU ml)71
PaO2
(Torr)
Active IPF 17 8?65 565 69?1
Inactive IPF 15 5?35 390** 80?4**
*Data are presented as the median values.
**P50?05 compared with active IPF by Mann–Whitney
U-test.
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active and inactive groups (Table 3). As a result, no
significant difference was found in the serum anti-p53
antibody level between the active (n¼17) and inactive
(n¼15) IPF groups (P50?265), while there were statistically
significant differences in serum LDH and arterial PaO2)
levels between these groups (P50?05).
Discussion
In this study, we measured the serum anti-p53 antibody
levels in patients with various lung diseases and normal
volunteers to evaluate the clinical significance of the serum
anti-p53 antibody in IPF, particularly with reference to
association with lung cancer. Comparing the serum anti-
p53 antibody level among the types of lung disease, the
median value in lung cancer was significantly higher than in
non-lung cancer IPF, PE and healthy controls, whereas
statistical differences were not found between IPF (with or
without lung cancer) and pulmonary emphysema. How-
ever, when the cut-off value was set at 7?7 on the basis of
the 95% specificity level for the normal control, the
incidences of elevated anti-p53 antibody levels were
significantly higher in lung cancer (61?2%), IPF with lung
cancer (57?1%) and IPF without lung cancer (53?1%) than
in PE (21?7%). These incidences of positive sera described
here were higher than those reported in previous studies on
lung cancer series (6,14). Although we cannot exclude the
possibility of variations due to sampling or bias in the
patient selection, such difference in incidence from those in
our study may be readily explained by differences of
methodology and setting for cut-off values in the other
studies. Winter et al. reported that anti-p53 antibodies were
found in the sera in 13% of the patients with lung cancer by
immunoblotting assay (6). Schlichtholz et al. employed the
anti-p53 antibody level of positive sera detected by both
immunoprecipitation and Western blotting as the cut-off
value in their ELISA data, and showed that anti-p53
antibodies were detected in the sera in 24% of the patients
with lung cancer as well as by ELISA assay (14). Indeed, it
is very important to confirm the presence of anti-p53
antibody in the serum by such assays as immunoprecipita-
tion and immunoblotting to obtain more convincing
results. However, these assays are likely to be far lesssensitive for the detection of target molecules than the
ELISA, thereby increasing the false-negative rate for the
detection of anti-p53 antibody. Furthermore, we think it
essential to consider the distribution of the anti-p53
antibody index of normal controls as well as the cancer
patient group to set the cut-off value. Therefore, from the
statistical viewpoint, it is theoretical that cut-off value is
determined by the 95% specificity approach or the ROC
curve analysis based on the data of cancer patients and
normal control subjects.
In the present study, it is noteworthy that the incidence of
positive anti-p53 antibody in the non-cancer IPF group
(53?1%) was almost as high as that in the group of lung
cancer (61?2%) or IPF with lung cancer (57?1%). The
presence of anti-p53 antibody has been associated with the
accumulation of mutant p53 proteins in the tumour and is
considered to be a marker for the presence of these
mutations (6,7), although anti-p53 antibodies recognize
both wild-type and mutant p53 proteins and the main
immunogenic epitopes are at the p53 protein termini, not at
the core domain where the majority of p53 mutations occur
(23). Immunohistochemical analysis has shown that p53 is
expressed especially in hyperplastic bronchial and alveolar
epithelial cells in IPF (21). Further analysis has demon-
strated that point mutations of the p53 gene are detected in
lung tissue samples with overexpression of the p53 protein
in IPF (22). These findings suggest that during the long
clinical course of IPF, chronic damage to the DNA may
result in mutation of the p53 gene, leading to accumulation
of the p53 protein and subsequent induction of anti-p53
antibody production. Furthermore, p53 mutations in IPF
may be occurring as frequently as in lung cancer, suggesting
that pulmonary fibrosis may be a precancerous lesion with
frequent mutations of the p53 gene. A previous report has
also shown that the presence of p53 gene mutations is
detected in premalignant bronchial lesions, such as those of
mild and severe epithelial dysplasias (28). These findings
may account for a high incidence of lung cancer complicat-
ing IPF.
Our results showed that the serum anti-p53 antibody
level in IPF was not correlated with clinical parameters,
such as the LDH and PaO2 levels. This suggests that the
serum anti-p53 antibody levels are unlikely to reflect the
disease activities of IPF. In addition, association with lung
cancer is one of the critical causes of death in IPF, and early
detection of lung cancer should always be considered in the
clinical care of IPF patients. We were able to obtain serum
samples for measurement of the anti-p53 antibody before
and after detection of cancer in only two individual cases of
IPF. In one case, the serum anti-p53 antibody level after the
detection of lung cancer was elevated in comparison with
that before detection, while in another case, there was no
change in the values between before and after the detection
of lung cancer. This suggests that a routine check of the
serum anti-p53 antibody level in IPF patients may be
helpful in the early detection of lung cancer, but a large
cohort study will be needed to address these issues and
determine the true correlation.
In conclusion, in our study using a series of serum
samples from patients with various lung diseases including
SERUM ANTI-P53 ANTIBODY AND IPF 1091lung cancer, IPF with or without lung cancer and PE, the
incidence of positive anti-p53 antibody in IPF, irrespective
of the existence of lung cancer, was as high as that in lung
cancer. This result suggests that IPF may be a premalignant
disease with frequent mutations of the p53 gene, which can
account for a high prevalence of lung cancer complicating
IPF.
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